NEW YORK, Jan. 20, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Universal Health Services, Inc. (“Universal Health” or the “Company”) (NYSE:UHS) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Universal Health securities from February 26, 2015 through December 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/uhs.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Universal Health admitted patients based on its own financial considerations and not the patient’s medical needs; (2) Universal Health would keep patients admitted until their insurance payments ran out in order to bill for the maximum of its services; (3) accordingly, Universal Health’s revenues from inpatient care relied on unjustifiable practices; (4) due to the aforementioned, Universal Health lacked efficient internal control regarding its practices and policies of admitting patients; and (5) consequently, Universal Health’s public statements were materially false and misleading at all relevant times.
On December 7, 2016 BuzzFeed released its investigation into Universal Health “…based on interviews with 175 current and former UHS staff, including 18 executives who ran UHS hospitals; more than 120 additional interviews with patients, government investigators, and other experts; and a cache of internal documents.” BuzzFeed reported that “[c]urrent and former employees from at least 10 UHS hospitals in nine states said they were under pressure to fill beds by almost any method – which sometimes meant exaggerating people’s symptoms or twisting their words to make them seem suicidal – and to hold them until their insurance payments ran out.” Following this news, Universal Health stock dropped $15.01 per share or nearly 12% to close at $111.36 on December 7, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/uhs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Universal Health you have until February 21, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 



